Production (Stage)
Coeptis Therapeutics Holdings, Inc.
COEP
$8.23
-$0.13-1.56%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | 62.90K | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 62.90K | -- | -- | -- | -- |
Cost of Revenue | 45.20K | -- | -- | -- | -- |
Gross Profit | 17.70K | -- | -- | -- | -- |
SG&A Expenses | 3.74M | 1.57M | 1.08M | 2.43M | 1.90M |
Depreciation & Amortization | 250.00K | 250.00K | 250.00K | -- | 250.00K |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 4.12M | 2.16M | 2.14M | 2.83M | 2.92M |
Operating Income | -4.06M | -2.16M | -2.14M | -2.83M | -2.92M |
Income Before Tax | -3.42M | -3.01M | -1.83M | -3.04M | -3.00M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -3.42M | -3.01M | -1.83M | -3.04M | -3.00M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | 363.20K | 1.06M | -- | -- | -- |
Net Income | -3.06M | -1.95M | -1.83M | -3.04M | -3.00M |
EBIT | -4.06M | -2.16M | -2.14M | -2.83M | -2.92M |
EBITDA | -3.76M | -1.91M | -1.89M | -2.58M | -2.67M |
EPS Basic | -1.00 | -0.95 | -0.92 | -1.62 | -1.69 |
Normalized Basic EPS | -0.58 | -0.34 | -0.56 | -1.01 | -1.06 |
EPS Diluted | -1.00 | -0.95 | -0.92 | -1.62 | -1.69 |
Normalized Diluted EPS | -0.58 | -0.34 | -0.56 | -1.01 | -1.06 |
Average Basic Shares Outstanding | 3.07M | 2.05M | 1.99M | 1.88M | 1.78M |
Average Diluted Shares Outstanding | 3.07M | 2.05M | 1.99M | 1.88M | 1.78M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |